Evolution of nanomedicine formulations for targeted delivery and controlled release
Advanced Drug Delivery Reviews · 2023-09 · 200 · 114962
DOI: 10.1016/j.addr.2023.114962 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2023-09. Verfasst von Sanyogitta Puri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Nanomedicine, Nanoparticles. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 149 Literaturangaben. Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Nanotechnology research over the past several decades has been aimed primarily at improving the physicochemical properties of small molecules to produce druggable candidates as well as for tumor targeting of cytotoxic molecules. The recent focus on genomic medicine and the success of lipid nanoparticles for mRNA vaccines have provided additional impetus for the development of nanoparticle drug carriers for nucleic acid delivery, including siRNA, mRNA, DNA, and oligonucleotides, to create therapeutics that can modulate protein deregulation. Bioassays and characterizations, including trafficking assays, stability, and endosomal escape, are key to understanding the properties of these novel nanomedicine formats. We review historical nanomedicine platforms, characterization methodologies, challenges to their clinical translation, and key quality attributes for commercial translation with a view to their developability into a genomic medicine. New nanoparticle systems for immune targeting, as well as in vivo gene editing and in situ CAR therapy, are also highlighted as emerging areas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Electronic address: mariarosa.mazza@astrazeneca.com.
- Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Biologics Engineering, Oncology R&D, United States.
- Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Macclesfield, UK.
- Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.
- Emerging Innovations Unit, Discovery Sciences, Biopharmaceutical R&D , AstraZeneca, Gaithersburg, MD, USA.
Förderung
- AstraZeneca
Zitieren
APA
Puri, S., Mazza, M., Roy, G., England, R. M., Zhou, L., Nourian, S., & Anand Subramony, J. (2023). Evolution of nanomedicine formulations for targeted delivery and controlled release. Advanced Drug Delivery Reviews, 200, 114962. https://doi.org/10.1016/j.addr.2023.114962
Vancouver
Puri S, Mazza M, Roy G, England RM, Zhou L, Nourian S, et al. Evolution of nanomedicine formulations for targeted delivery and controlled release. Advanced Drug Delivery Reviews. 2023;200:114962. doi:10.1016/j.addr.2023.114962
BibTeX
@article{Puri2023,
author = {Puri, Sanyogitta and Mazza, Mariarosa and Roy, Gourgopal and England, Richard M and Zhou, Liping and Nourian, Saghar and Anand Subramony, J},
title = {Evolution of nanomedicine formulations for targeted delivery and controlled release},
journal = {Advanced Drug Delivery Reviews},
year = {2023},
volume = {200},
pages = {114962},
doi = {10.1016/j.addr.2023.114962}
}
EUVIMED